Results 131 to 140 of about 54,960 (249)
Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions
MedComm, Volume 7, Issue 4, April 2026.Antibody–drug conjugates integrate antibody targeting with potent cytotoxic payloads to enable precision cancer therapy. Their clinical performance depends on coordinated optimization of engineering design, tumor antigen biology, and treatment strategy. Lessons from uro‐oncological malignancies illustrate how ADCs can be effectively developed, combined,
Bisheng Cheng +6 more
wiley +1 more source
Focal Spot, Spring/Summer 1980 [PDF]
, 1980 https://digitalcommons.wustl.edu/focal_spot_archives/1026/thumbnail ...
core +1 more source
Targeted Therapies for Each Subtype of Breast Cancer
MedComm, Volume 7, Issue 4, April 2026.This review systematically summarizes the advances in targeted therapies for the three major molecular subtypes of breast cancer (BC), highlighting key strategies, agents, and clinical progress to guide personalized treatment. HR‐positive (luminal) BC: Dominated by estrogen receptor (ER) signaling, with endocrine therapies as the cornerstone—including ...
Aiyu Liu +5 more
wiley +1 more source
Medical Physics, Volume 53, Issue 4, April 2026.Abstract Background Independent verification of the manufacturer‐provided dosimetry data for 106Ru ophthalmic brachytherapy applicators is crucial for safe and accurate treatment, yet a standardized, traceable method for clinical absolute dosimetry has been lacking. Purpose This work establishes a complete framework for traceable absorbed dose to water
Simon Dahlander +5 more
wiley +1 more source
Impact of partial volume correction on radiomics reproducibility in theranostic SPECT/CT imaging
Medical Physics, Volume 53, Issue 4, April 2026.Abstract Background: Radiomics has shown potential for quantitative characterization of tumors in molecular imaging; however, its clinical translation in theranostic 177Lu SPECT/CT remains limited due to poor robustness of extracted features to reconstruction variability and partial volume effects.
Mohammad Saber Azimi +11 more
wiley +1 more source
Small Science, Volume 6, Issue 4, April 2026.Intercalation of At‐211 between the layers of K‐ or Cs‐zirconium phosphate. The ion exchange behavior of K‐ and Cs‐derivatives of α‐zirconium phosphate, A‐ZrP, with the targeted alpha therapy (TAT) radionuclide 211At, as At+ and AtO+, has been investigated. The K‐ZrP shows strong affinity for both At+ and AtO+, ≥99% uptake.
B. D. Imansha Madhushan +10 more
wiley +1 more source
Cutting‐edge advances in bicyclic peptide‐based radiotracers for cancer imaging and theranostics
VIEW, Volume 7, Issue 2, April 2026.Bicyclic peptides, a burgeoning subset of bicyclic macrocycles, are characterized by two loops stabilized through three linkages of the central chemical scaffolds. As an immense potential platform for radiotracers development, bicyclic peptide‐based radiotracers have yielded encouraging results in preclinical and clinical trial studies.
Hengyi Ou, Xiaobo Wang, Fei Kang
wiley +1 more source
Thoracic Cancer, Volume 17, Issue 8, April 2026.Implementation of a dedicated neuroendocrine cancer service in South Wales significantly shortened diagnostic and treatment timelines for bronchopulmonary NETs, demonstrating the benefits of coordinated specialist input. ABSTRACT Background Bronchopulmonary neuroendocrine tumors (bpNETs) are uncommon lung neoplasms posing significant diagnostic and ...
Arouba Imtiaz +7 more
wiley +1 more source
Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 199-206, April 2026.ABSTRACT Objective 177Lu‐PSMA radioligand therapy (RLT) is increasingly used to treat metastatic castration‐resistant prostate cancer (mCRPC). Posttreatment dosimetry is essential for assessing normal organ absorbed doses. Therefore, this study aims to evaluate normal organs dosimetry in mCRPC patients undergoing 177Lu‐PSMA‐RLT from two university ...
Onnicha Pattanawong +6 more
wiley +1 more source